An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-164, an Antibody-Drug Conjugate, in Patients with Advanced Gastrointestinal Cancers Expressing Guanylyl Cyclase C
This Study is
No Longer Enrolling
Details
Age
Adult
Phase
I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.
Type of Study
Treatment
Locations
University of Colorado Hospital
Study ID
Protocol Number: 17-2226
More information available at ClinicalTrials.gov: NCT03449030
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers